Gastric dumping syndrome medical therapy
Gastric dumping syndrome Microchapters |
Differentiating Gastric dumping syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Gastric dumping syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Gastric dumping syndrome medical therapy |
Risk calculators and risk factors for Gastric dumping syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Umar Ahmad, M.D.[2]
Overview
The main therapy for the management of dumping syndrome includes diet and pharmacological intervention.
Approach to Management
The following algorithm demonstrates the course of action in the approach of the management of dumping syndrome:
Gastric or Esophageal Surgery | |||||||||||||||||||||||||||||||||||||||||||||||
Early dumping syndrome | Late dumping syndrome | ||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis | Measure Glucose | ||||||||||||||||||||||||||||||||||||||||||||||
Confirm diagnosis with OGTT | |||||||||||||||||||||||||||||||||||||||||||||||
Dietary modifications | Dietary supplements | ||||||||||||||||||||||||||||||||||||||||||||||
Acarbose | |||||||||||||||||||||||||||||||||||||||||||||||
Treatment | Somatostatin analogues | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment refractory dumping syndrome | |||||||||||||||||||||||||||||||||||||||||||||||
Surgical re-intervention or Continuous enteral feeding | |||||||||||||||||||||||||||||||||||||||||||||||
Medical Therapy
Medical therapy for dumping syndrome includes diet and drug therapy.[1]
Level of evidence | Type of evidence |
---|---|
I | Evidence from meta-analysis of multiple, well-designed, controlled studies (randomized trials with low false-positive and low false-negative errors) |
II | Evidence from at least 1 well-designed, quasi-experimental study (randomized trials with high false-positive and high false-negative errors) |
III | Evidence from well-designed, quasi-experimental studies (nonrandomized, controlled, single-group, pre–post, cohort and time or matched case–control series) |
IV | Evidence from well-designed, non-experimental studies (comparative and correlational descriptive and case studies) |
V | Evidence from case reports |
Grade of recommendation | Level of evidence |
A | Level I evidence or consistent findings from multiple studies (level II, III or IV) |
B | Level II, III or IV evidence with generally consistent findings |
C | Level II, III or IV evidence with inconsistent findings |
D | Little or no systematic empirical evidence |
Diet
Dietary Modifications (Level III; Grade B)
- Decrease carbohydrate intake
- Avoid simple sugars like soda, candy sweets, and cookies
- Fluid restriction
- Wait at least 30 minutes after a meal before drinking
- Increase protein intake
- Increase fat intake
- Increase fiber intake
- Dairy and dairy product restriction
- Shorter meals
- Eat slowly
- Chew properly
- Lying supine for 30 minutes after a meal
- Glycemic index education of foods is important
Dietary Supplements (Level III; Grade C)
The following work similarly to each other. These supplements increase viscosity which in turn decreases gastric emptying and causes a delay in glucose absorption.
- Delay glucose absorption:
- Pectin
- 15 grams of Pectin is effective
- Guar gum
- 15 grams of Guar gum is effective
- Glucomannan
- Glucomannan improves glucose tolerance but isn't as effective
- Pectin
- The increased fiber in the supplements leads to gas and bloating. This decreases tolerability and in turn reduces compliance.
Dietary Foods
The following is a table that illustrates the types of food to take and avoid in the case of dumping syndrome.
Breads, Cereals, Rice and Pasta | Foods To Choose | Foods to Avoid |
---|---|---|
|
|
|
Fruits | Foods to Choose | Foods To Avoid |
|
|
|
Milk and Dairy Products | Foods To Choose | Foods to Avoid |
|
|
|
Meats, Poultry, Fish, Dry Beans, Peas, Eggs and Cheese | Foods to Choose | Foods to Avoid |
|
|
|
Vegetables | Foods to Choose | Foods to Avoid |
|
|
|
Fats, Condiments and Beverages | Foods to Choose | Foods to Avoid |
|
| |
Snacks, Sweets, and Desserts | Foods to Choose | Foods to Avoid |
|
Drug Therapy
Although there are no FDA approved medications specific for dumping syndrome the following pharmacological interventions are used off-label:
- Acarbose (Glucobay, Precose, Prandase)
- Somatostatin analogues such as Octreotide (Sandostatin)
Acarbose (Level III; Grade B) | Octreotide (Level II; Grade A) | |
---|---|---|
Use | Late dumping syndrome | Early and Late dumping syndrome |
Mechanism of Action | Inhibits carbohydrate absorption | Strong inhibitor of the gut hormones (especially insulin) |
Dose |
|
|
Effect |
|
|
Additional information |
|
Somatostatin analogues
- Pasireotide has a higher receptor affinity than octreotide and is more effective but it does not reduce dumping syndrome symptoms as well as octreotide.
- Even though pasireotide has been safe and effective no results of its clinical trials have been published to date.
Drug summary
Drug | Dose | Effect |
---|---|---|
Tolbutamide[2] | 0.25-0.75 g, TID | Subjective improvement |
Propranolol[3] | 10 mg, QID | Reduced early dumping |
Cyproheptadine[4] | 4-8 mg, TID | Preventing vasomotor symptoms |
Methysergide maleate[5] | 4-8 mg, TID | Reduced vasomotor symptoms |
Verapamil[6] | 120-240 mg, QD | Reduced vasomotor symptoms |
Acarbose[7] | 50-100 mg, TID | Reduced late dumping |
Octreotide[8] | 25-100 mcg, TID | Reduced vasomotor symptoms |
Pantoprazole (PPI)[9] | Subjective improvement | |
Cholestyramine[10] | Subjective improvement | |
Diazoxide[11] | 75-260 mg, QD | Subjective improvement |
Nifedipine[12] | 30 mg, QD | Reduced hypoglycemic symptoms |
Exendin 9-39[13] | 7500 pmol/kg prime | Reduced hypoglycemic symptoms |
Effects of surgery on medications
- After RYGB surgery, bioavailability is decreased in drugs such as:[14][15][16][17][18]
- Surgeries that decrease the stomach size may increase toxicity of:
- Any procedure that leads to dumping syndrome will:
- Increases gut transit time
- Decease drug absorption
References
- ↑ Ukleja A (2005). "Dumping syndrome: pathophysiology and treatment". Nutr Clin Pract. 20 (5): 517–25. doi:10.1177/0115426505020005517. PMID 16207692.
- ↑ Sigstad H (1969). "Effect of tolbutamide on the dumping syndrome". Scand. J. Gastroenterol. 4 (3): 227–31. PMID 5346670.
- ↑ Niv Y (1988). "The early dumping syndrome and propranolol". Ann. Intern. Med. 108 (6): 910–1. PMID 3369789.
- ↑ Leichter SB, Permutt MA (1975). "Effect of adrenergic agents on postgastrectomy hypoglycemia". Diabetes. 24 (11): 1005–10. PMID 1183731.
- ↑ Bernard PF, Baschet C, Le Henand F, Bouderlique JR, Lortat-Jacob JL (1970). "[Treatment of 65 cases of dumping syndrome with methysergide in recently gastrectomized patients]". Presse Med (in French). 78 (12): 549–50. PMID 5439191.
- ↑ Tabibian N (1990). "Successful treatment of refractory post-vagotomy syndrome with verapamil (Calan SR)". Am. J. Gastroenterol. 85 (3): 328–9. PMID 2309689.
- ↑ Hasegawa T, Yoneda M, Nakamura K, Ohnishi K, Harada H, Kyouda T, Yoshida Y, Makino I (1998). "Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome". J. Gastroenterol. Hepatol. 13 (12): 1201–6. PMID 9918426.
- ↑ Vecht J, Masclee AA, Lamers CB (1997). "The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment". Scand. J. Gastroenterol. Suppl. 223: 21–7. PMID 9200302.
- ↑ Sanaka M, Yamamoto T, Kuyama Y (2010). "Effects of proton pump inhibitors on gastric emptying: a systematic review". Dig. Dis. Sci. 55 (9): 2431–40. doi:10.1007/s10620-009-1076-x. PMID 20012198.
- ↑ Barkun AN, Love J, Gould M, Pluta H, Steinhart H (2013). "Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment". Can. J. Gastroenterol. 27 (11): 653–9. PMC 3816948. PMID 24199211.
- ↑ Vilarrasa N, Goday A, Rubio MA, Caixàs A, Pellitero S, Ciudin A, Calañas A, Botella JI, Bretón I, Morales MJ, Díaz-Fernández MJ, García-Luna PP, Lecube A (2016). "Hyperinsulinemic Hypoglycemia after Bariatric Surgery: Diagnosis and Management Experience from a Spanish Multicenter Registry". Obes Facts. 9 (1): 41–51. doi:10.1159/000442764. PMC 5644871. PMID 26901345.
- ↑ Guseva N, Phillips D, Mordes JP (2010). "Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient". Endocr Pract. 16 (1): 107–11. doi:10.4158/EP09110.CRR. PMC 3979460. PMID 19625246.
- ↑ Salehi M, Gastaldelli A, D'Alessio DA (2014). "Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass". Gastroenterology. 146 (3): 669–680.e2. doi:10.1053/j.gastro.2013.11.044. PMC 3943944. PMID 24315990.
- ↑ Padwal R, Klarenbach S, Wiebe N, Hazel M, Birch D, Karmali S, Sharma AM, Manns B, Tonelli M (2011). "Bariatric surgery: a systematic review of the clinical and economic evidence". J Gen Intern Med. 26 (10): 1183–94. doi:10.1007/s11606-011-1721-x. PMC 3181300. PMID 21538168.
- ↑ Smith A, Henriksen B, Cohen A (2011). "Pharmacokinetic considerations in Roux-en-Y gastric bypass patients". Am J Health Syst Pharm. 68 (23): 2241–7. doi:10.2146/ajhp100630. PMID 22095812.
- ↑ Padwal R, Brocks D, Sharma AM (2010). "A systematic review of drug absorption following bariatric surgery and its theoretical implications". Obes Rev. 11 (1): 41–50. doi:10.1111/j.1467-789X.2009.00614.x. PMID 19493300.
- ↑ Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS (2012). "The effects of gastric bypass surgery on drug absorption and pharmacokinetics". Expert Opin Drug Metab Toxicol. 8 (12): 1505–19. doi:10.1517/17425255.2012.722757. PMID 22998066.
- ↑ Titus R, Kastenmeier A, Otterson MF (2013). "Consequences of gastrointestinal surgery on drug absorption". Nutr Clin Pract. 28 (4): 429–36. doi:10.1177/0884533613490740. PMID 23835364.